GALAPAGOS NV/S (NASDAQ:GLPG) Expected to Announce Earnings of $2.37 Per Share

Equities analysts expect GALAPAGOS NV/S (NASDAQ:GLPG) to report earnings per share (EPS) of $2.37 for the current quarter, according to Zacks. Five analysts have provided estimates for GALAPAGOS NV/S’s earnings, with estimates ranging from ($1.80) to $9.17. GALAPAGOS NV/S posted earnings of $0.33 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 618.2%. The business is expected to report its next earnings report on Friday, October 25th.

According to Zacks, analysts expect that GALAPAGOS NV/S will report full-year earnings of $3.29 per share for the current financial year, with EPS estimates ranging from ($4.46) to $9.54. For the next fiscal year, analysts expect that the business will report earnings of ($1.16) per share, with EPS estimates ranging from ($6.63) to $3.22. Zacks’ EPS calculations are an average based on a survey of research firms that follow GALAPAGOS NV/S.

Several equities analysts have recently weighed in on GLPG shares. BidaskClub upgraded GALAPAGOS NV/S from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 13th. Raymond James cut GALAPAGOS NV/S from a “strong-buy” rating to a “market perform” rating in a report on Monday, July 15th. UBS Group upgraded GALAPAGOS NV/S from a “neutral” rating to a “buy” rating in a report on Wednesday, July 31st. Morgan Stanley lifted their price objective on GALAPAGOS NV/S from $138.00 to $139.00 and gave the company an “overweight” rating in a report on Monday, April 29th. Finally, HC Wainwright lifted their price objective on GALAPAGOS NV/S from $150.00 to $205.00 and gave the company a “buy” rating in a report on Monday, July 15th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $156.45.



Shares of NASDAQ:GLPG traded down $0.02 during trading on Thursday, hitting $169.57. 85,675 shares of the company’s stock traded hands, compared to its average volume of 132,951. GALAPAGOS NV/S has a 52 week low of $85.00 and a 52 week high of $191.63. The company has a current ratio of 6.40, a quick ratio of 6.40 and a debt-to-equity ratio of 0.02. The firm has a market cap of $8.96 billion, a P/E ratio of -256.92 and a beta of 1.57. The firm has a 50-day simple moving average of $160.89.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Norges Bank bought a new stake in GALAPAGOS NV/S in the 4th quarter valued at approximately $6,422,000. Henry James International Management Inc. lifted its stake in GALAPAGOS NV/S by 3.7% in the 1st quarter. Henry James International Management Inc. now owns 20,719 shares of the biotechnology company’s stock valued at $2,440,000 after acquiring an additional 740 shares in the last quarter. Millennium Management LLC lifted its stake in GALAPAGOS NV/S by 14.6% in the 4th quarter. Millennium Management LLC now owns 72,538 shares of the biotechnology company’s stock valued at $6,655,000 after acquiring an additional 9,217 shares in the last quarter. Alps Advisors Inc. lifted its stake in GALAPAGOS NV/S by 14.5% in the 1st quarter. Alps Advisors Inc. now owns 87,116 shares of the biotechnology company’s stock valued at $10,261,000 after acquiring an additional 11,045 shares in the last quarter. Finally, Bessemer Group Inc. bought a new stake in GALAPAGOS NV/S in the 2nd quarter valued at approximately $48,447,000. Hedge funds and other institutional investors own 17.06% of the company’s stock.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

See Also: Penny Stocks

Get a free copy of the Zacks research report on GALAPAGOS NV/S (GLPG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.